Tissue Regenix strikes distribution deal in Italy

The AIM-traded firm said OrthoPure XT, a “decellularised xenograft ligament”, uses its patented ‘dCell’ technology as the only available non-human biologic graft indicated for certain ligament reconstruction procedures.

OrthoPure XT was commercially launched in December 2020 after being awarded a CE mark for revision of anterior cruciate ligament (ACL) reconstruction procedures and the reconstruction of other knee ligaments, including multiligament and primary procedures when the autograft was deemed unacceptable.

The biocompatible implant provides a “biomechanically appropriate” tissue scaffold for cellular repopulation and eventual regeneration, the company explained.

It said the multiyear distribution agreement covered Italy currently, but also had the potential for extension to wider geographies.

As part of the deak, Geistlich committed to advance the clinical science surrounding OrthoPure XT, which would be conducted at “some of the leading institutions” by clinicians in Italy.

“Geistlich is a leader in regenerative products, so our commitments are aligned in delivering innovative products to advance patient care,” said chief executive officer Daniel Lee.

“We are excited to work with them to build the clinical experience with OrthoPure XT and introduce this transformative product to the Italian medical community.”

At 1327 GMT, shares in Tissue Regenix Group were up 10% at 0.37p.